Business Context and Reporting Period
This Form 8-K is a current report filed by RXi Pharmaceuticals Corporation (also referenced as Phio Pharmaceuticals Corp. in metadata) on March 29, 2017. The filing discloses a presentation made by company representatives at the 2nd Annual Oligonucleotide and Peptide Therapeutics Conference in Cambridge, Massachusetts.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses solely on regulatory disclosure of a conference presentation and does not contain financial statements or performance data.
Material Changes
No material changes to financial position or operations are reported in this document. The filing serves to disclose non-financial information regarding a corporate presentation.
Guidance, Outlook, and Risks
Management commentary is limited to the disclosure that a presentation was delivered at an industry conference. The full content of the presentation is attached as Exhibit 99.1. The filing explicitly states that the information in Item 7.01 and Exhibit 99.1 is not treated as "filed" under Section 18 of the Exchange Act and will not be incorporated by reference into other filings unless expressly stated.
Key Facts for Investor Verification
- Verify the content of the conference presentation attached as Exhibit 99.1 for specific business updates.
- Note that the information disclosed in this 8-K is not subject to the liabilities of Section 18 of the Exchange Act.
- Confirm the company's current name and ticker status, as the filing header lists "RXi Pharmaceuticals Corporation" while metadata references "Phio Pharmaceuticals Corp."